will it close out with, page-22

"Actually, we have a very limited, but we think exciting piece of data that says that it (ddRNAi) might be efficacious .... we have the opportunity to use now ddRNAi in combination or alone, as a stand alone technology for long term treatment of HIV infection and I see that this is something that really needs to be exploited"

John Rossi speaking about the Phase I HIV clinical trial.

Sounds to me like some of the additional patients are being dosed with ddRNAi alone. Or am I just reading too much into this? What will happen to BLT's share price when they publish this piece of data they have from the original trial? A trial which incidentially, BLT own the rights too.